Similarly, the proportion of patients who experienced ≥1 moderate-to-severe exacerbation was numerically lower with aclidinium compared with placebo in each study; however, these results did not reach statistical significance at the study level or overall ( Table 3 ).
← all excerpts
Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies.
1
—
—